SynthesisScientific reports2025
A systematic review and meta-analysis of shugan jieyu capsule combined with escitalopram in the treatment of senile depression.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dose-response efficacy of horticultural therapy for geriatric depression: a systematic review and meta-analysis of randomized controlled trials.Frontiers in public health · 2026Pooled it
- Raphe subregion seeds reveal whole-brain functional connectivity differences underlying adolescent depression.BMC psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
To evaluate the synergistic effect of the Shugan Jieyu Capsule combined with Escitalopram in the treatment of senile depression. The study protocol has been registered in PROSPERO with registration number CRD42023440270. Eight databases, including PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Network (CNKI), China Biomedical Literature Database (CBM), VIP database, and Wanfang Database, were searched, respectively. Randomized controlled trial (RCTs) of the Shugan Jieyu Capsule combined with Escitalopram in the treatment of senile depression was included. The search time was from the listing of Shugan Jieyu Capsule (2009) to January 1, 2025. Outcome measures included Total effective rate, Hamilton Depression Scale (HAMD) score, Hamilton Anxiety Scale (HAMA) score, serum 5-hydroxytryptamine (5-HT), serum norepinephrine (NE), and Incidence of adverse reactions. The treatment period should be at least 6 weeks. Data extraction and methodological quality evaluation were carried out for the included literature, and statistical analysis was performed using RevMan 5.3 software. Finally, the Grading of Recommendations Assessment, Development and Evaluation (GRADE ) system was used to assess the quality of the evidence. A total of 8 RCTs were included in the study, with a total of 765 patients. The results of this meta-analysis showed that the combination of Shugan Jieyu Capsule and Escitalopram could improve Total effective rate [OR = 4.25, 95%CI(2.53, 7.14), P<0.00001] and reduce HAMD score in terms of clinical symptom indicators [SMD=-1.26, 95%CI(-1.45, -1.08), P<0.00001], and decrease HAMA score [SMD=-0.82, 95%CI(-1.05, -0.59), P<0.00001]. In terms of laboratory indexes, serum 5-HT levels could be increased in the combined group [MD = 31.92, 95%CI(28.34, 35.50), P < 0.00001]. In terms of safety, no serious adverse reactions were observed in both group, and the incidence of adverse reactions was lower in the combined group [OR = 0.62, 95%CI(0.42, 0.92), P = 0.02]. During the treatment period of 12 weeks, Shugan Jieyu Capsule combined with Escitalopram had a good effect in the treatment of senile depression, which could significantly reduce HAMD and HAMA scores of senile depression. In addition, the combined application of the two drugs can help to increase the level of serum 5-HT, without increasing the occurrence of adverse events, and has a good application prospect.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.